company background image
NXSC.F logo

Next Science OTCPK:NXSC.F Stock Report

Last Price

US$0.10

Market Cap

US$28.8m

7D

0%

1Y

-35.9%

Updated

07 Nov, 2024

Data

Company Financials +

Next Science Limited

OTCPK:NXSC.F Stock Report

Market Cap: US$28.8m

NXSC.F Stock Overview

Engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand.

NXSC.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Next Science Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Next Science
Historical stock prices
Current Share PriceAU$0.10
52 Week HighAU$0.27
52 Week LowAU$0.089
Beta1.43
11 Month Change-9.42%
3 Month Change-48.08%
1 Year Change-35.90%
33 Year Change-89.47%
5 Year Change-93.38%
Change since IPO-93.71%

Recent News & Updates

Recent updates

Shareholder Returns

NXSC.FUS Medical EquipmentUS Market
7D0%1.1%2.3%
1Y-35.9%29.2%35.1%

Return vs Industry: NXSC.F underperformed the US Medical Equipment industry which returned 27.5% over the past year.

Return vs Market: NXSC.F underperformed the US Market which returned 31.5% over the past year.

Price Volatility

Is NXSC.F's price volatile compared to industry and market?
NXSC.F volatility
NXSC.F Average Weekly Movementn/a
Medical Equipment Industry Average Movement8.1%
Market Average Movement6.2%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.9%

Stable Share Price: NXSC.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine NXSC.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012n/aI.V. Hallwww.nextscience.com

Next Science Limited engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial gel that conforms to the postoperative wound; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.

Next Science Limited Fundamentals Summary

How do Next Science's earnings and revenue compare to its market cap?
NXSC.F fundamental statistics
Market capUS$28.80m
Earnings (TTM)-US$13.50m
Revenue (TTM)US$23.31m

1.2x

P/S Ratio

-2.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NXSC.F income statement (TTM)
RevenueUS$23.31m
Cost of RevenueUS$4.93m
Gross ProfitUS$18.37m
Other ExpensesUS$31.87m
Earnings-US$13.50m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.046
Gross Margin78.83%
Net Profit Margin-57.93%
Debt/Equity Ratio0%

How did NXSC.F perform over the long term?

See historical performance and comparison